Small-cap health care company Tango Therapeutics has moved 8.4% Friday, reaching $3.74 per share. In contrast, the average analyst target price for the stock is $15.2.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company is based in the United States.
Make Sure to Consider the Following Before Buying Tango Therapeutics:
-
Tango Therapeutics has moved -15.0% over the last year.
-
TNGX has a forward P/E ratio of -2.5 based on its EPS guidance of -1.52.
-
Over the last 3 years, earnings per share (EPS) have been growing at a compounded average rate of -31.8%.
-
Its Price to Book (P/B) ratio is 1.45
Tango Therapeutics Has an Unconvincing Cash Flow History
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | -109,080 | -7,692 | -116,772 | -90.29 |
| 2021-12-31 | -59,527 | -1,837 | -61,364 | -188.97 |
| 2020-12-31 | 70,074 | -1,106 | 68,968 | n/a |
Tango Therapeutics's recent cash flow history is disappointing. They've averaged $-36.39 Million over the last 3 years while displaying a coefficient of variability of 262.0%. During this time, they grew at a -27.2% compounded yearly rate
